Medical equipment maker ResMed will pay $37.5 million to resolve allegations brought by the Department of Justice (DOJ) that it paid kickbacks to durable medical equipment suppliers, sleep labs and ...
ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android ...
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, ...
"I have little doubt that Mick and Rob will build on ResMed's momentum as a global driving force in sleep and respiratory medicine, and as a leader in the medical device industry," said Dr. Peter ...
CEO Mick Farrell highlighted strong financial performance, with revenue growth, gross margin expansion, and robust free cash flow generation. He attributed this to disciplined execution and momentum ...
ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from its major competitor. Despite a strong last quarter ...
ResMed faces tough competition, though, particularly from Philips (formerly Respironics). Respironics pioneered the industry and possesses admirable marketing and distribution capabilities.
ResMed Inc's (CHESS) (ASX:RMD) new S+ product app will be part of an Apple HealthKit, opening up a huge consumer market for e-health tech. ResMed is a leading producer of breathing aids and ...
ResMed chief executive Mick Farrell says diversifying into digital health and the treatment of new diseases is the right strategy and will improve profitability even as investor angst grows that he is ...
Add articles to your saved list and come back to them any time. Medtech giant ResMed is expanding its focus to fighting insomnia as it doubles down on digital health investments after another year of ...
SAN DIEGO & AUCKLAND, New Zealand--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent ...
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback